BASALIN Trademark

Trademark Overview

On Thursday, July 25, 2013, a trademark application was filed for BASALIN with the United States Patent and Trademark Office. The USPTO has given the BASALIN trademark a serial number of 79136321. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Monday, April 7, 2025. This trademark is owned by Gan & Lee Pharmaceuticals Ltd.. The BASALIN trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for human purposes, namely, insulin; raw material medicine, namely, insulin; Biomedicine for treating diabetes; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Biological preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines cognitive disorders; chemical preparations for medical purposes, namely, for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Chemical preparations for pharmace...

General Information

Serial Number79136321
Word MarkBASALIN
Filing DateThursday, July 25, 2013
Status706 - SECTION 71 ACCEPTED
Status DateMonday, April 7, 2025
Registration Number4615574
Registration DateTuesday, October 7, 2014
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, July 22, 2014

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesMedicines for human purposes, namely, insulin; raw material medicine, namely, insulin; Biomedicine for treating diabetes; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Biological preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines cognitive disorders; chemical preparations for medical purposes, namely, for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Chemical preparations for pharmaceutical purposes, namely, for the treatment of endocrine related diseases and disorders; Pharmaceutical preparations, namely, insulin for injection; [ dietetic substances, namely, dietetic sugar, pasta and crackers adapted for medical use; ] drugs, namely, anti-diabetic pharmaceuticals for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 9, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGan & Lee Pharmaceuticals.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressTongzhou D., Beijing 100110
CN
Party NameGan & Lee Pharmaceuticals Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCN
Party NameGan & Lee Pharmaceuticals Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCN

Trademark Events

Event DateEvent Description
Thursday, October 3, 2013SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, October 9, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 15, 2013APPLICATION FILING RECEIPT MAILED
Friday, November 8, 2013ASSIGNED TO EXAMINER
Thursday, November 14, 2013NON-FINAL ACTION WRITTEN
Friday, November 15, 2013NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, November 18, 2013REFUSAL PROCESSED BY MPU
Monday, November 18, 2013NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, December 10, 2013REFUSAL PROCESSED BY IB
Monday, December 9, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 9, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 10, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 11, 2013SUSPENSION LETTER WRITTEN
Wednesday, December 11, 2013LETTER OF SUSPENSION E-MAILED
Wednesday, December 11, 2013NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, June 11, 2014ASSIGNED TO LIE
Wednesday, June 18, 2014SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, June 19, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 19, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, July 2, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, July 2, 2014NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, July 2, 2014NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, July 22, 2014PUBLISHED FOR OPPOSITION
Tuesday, July 22, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 22, 2014NOTIFICATION PROCESSED BY IB
Tuesday, October 7, 2014REGISTERED-PRINCIPAL REGISTER
Wednesday, January 7, 2015FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, March 11, 2015FINAL DISPOSITION PROCESSED
Wednesday, March 11, 2015FINAL DISPOSITION NOTICE SENT TO IB
Friday, April 3, 2015FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, June 1, 2015CORRECTION TRANSACTION RECEIVED FROM IB
Tuesday, June 2, 2015CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Friday, April 7, 2017CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, October 7, 2019COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, October 2, 2020TEAS SECTION 71 RECEIVED
Sunday, January 10, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, January 11, 2021REGISTERED-SEC.71 ACCEPTED
Monday, January 11, 2021NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Saturday, September 11, 2021PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Monday, September 27, 2021INVALIDATION PROCESSED
Monday, September 27, 2021PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Wednesday, November 3, 2021PARTIAL INVALIDATION PROCESSED BY THE IB
Friday, May 12, 2023INTERNATIONAL REGISTRATION RENEWED
Saturday, October 7, 2023COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Thursday, November 7, 2024TEAS SECTION 71 RECEIVED
Friday, January 24, 2025NEW REPRESENTATIVE AT IB RECEIVED
Monday, April 7, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, April 7, 2025REGISTERED-SEC.71 ACCEPTED
Monday, April 7, 2025NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Thursday, June 19, 2025NEW REPRESENTATIVE AT IB RECEIVED
Sunday, December 7, 2025PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

Related Keywords

basalin diseases disorders preparations treatment diabetes namely ocular based bacteria prevention